|The VEGF165 vegfa (Catalog #MBS8500092) is an Antibody produced from Rabbit and is intended for research purposes only. The product is available for immediate purchase. The VEGF165 Polyclonal Antibody reacts with Human and may cross-react with other species as described in the data sheet. MyBioSource\'s VEGF165 can be used in a range of immunoassay formats including, but not limited to, ELISA (EIA), Western Blot (WB).
WB: 1:1000-5000. Researchers should empirically determine the suitability of the VEGF165 vegfa for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
The VEGF165 vegfa product has the following accession number(s) (GI #19909065) (NCBI Accession #AAM03108.1). Researchers may be interested in using Bioinformatics databases such as those available at The National Center for Biotechnology Information (NCBI) website for more information about accession numbers and the proteins they represent. Even researchers unfamiliar with bioinformatics databases will find the NCBI databases to be quite user friendly and useful.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Please refer to the product datasheet for known applications of a given antibody. We\'ve tested the VEGF165 Polyclonal Antibody with the following immunoassay(s):
Western Blot (WB) (WB Assay 1st antibody: E14-05, dilution: 1:5000 2nd antibody: Goat antibody against Rabbit IgG conjugated with HRP, dilution: 1:5000, visualized by DAB Protein Molecular Wt.: 21 kDa M: Pre-stained protein marker 1: Recombinant human VEGF165)
Vascular endothelial growth factor (VEGF), also known as vascular permeability factor (VPF), is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult. VEGF is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis and endothelial cell growth, promoting cell migration, and inhibiting apoptosis. Six forms of human VEGF mRNA encoding VEGF proteins of 121, 145, 165, 183, 189, and 206 amino acids are produced from a single gene as a result of alternative splicing. VEGF165 appears to be the major gene product found in human tissue and is the most effective angiogenic factor in the VEGF family.
Immunogen: Recombinant human VEGF165, 27~191 aa of VEGF. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing VEGF165 are readily searchable from our website. Different antibodies against the same target such as VEGF165 may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results. VEGF165 also interacts with the following gene(s): FLT1, HIF1A, IGF1, KDR, MMP9, NRP1, PGF, SRC, TGFB1, VWF. Choroidal Neovascularization, Diabetes Complications, Diabetic Retinopathy, Heart Diseases, Inflammation, Lung Diseases, Macular Edema, Neoplasm Metastasis, Neovascularization, Pathologic, Retinal Diseases are some of the diseases may be linked to VEGF165 Polyclonal Antibody.